Biopharmaceutical company, Corbus Pharmaceuticals Holdings, Inc., has been making strides in its mission to combat serious illnesses through product development. The firm is currently working on CRB-701, an innovative antibody drug conjugate (ADC) that aims to tackle cancer cells. In Phase I clinical trial, CRB-701 targets Nectin-4 expression and releases a cytotoxic payload of monomethyl auristatin E (MMAE). Additionally, Corbus Pharmaceuticals is developing CRB-601, an anti-integrin monoclonal antibody to fight solid tumors, and CRB-913, an endocannabinoid small molecule drug crafted to treat obesity and related metabolic diseases. The firm also has its eyes set on lenabasum, a promising oral molecule that selectively activates cannabinoid receptor type 2 (CB2) and is currently in Phase II clinical trial for use in inflammation and fibrosis treatment. Jenrin Discovery, LLC and Corbus Pharmaceuticals have a partnership which permits the development and marketing of licensed products such as the Jenrin library of approximately 600 compounds, as well as issued and pending patent filings. The Norwood, Massachusetts-based company was established in 2009.
Corbus Pharmaceuticals Holdings's ticker is CRBP
The company's shares trade on the NASDAQ stock exchange
They are based in Norwood, Massachusetts
There are 1-10 employees working at Corbus Pharmaceuticals Holdings
It is http://www.corbuspharma.com/
Corbus Pharmaceuticals Holdings is in the Healthcare sector
Corbus Pharmaceuticals Holdings is in the Biotechnology industry
The following five companies are Corbus Pharmaceuticals Holdings's industry peers: